{
    "clinical_study": {
        "@rank": "62059", 
        "arm_group": [
            {
                "arm_group_label": "IDeg Fixed dosing - Stepwise titration", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IDeg Flexible dosing - Stepwise titration", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IDeg Fixed dosing - Simple titration", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IDeg Flexible dosing - Simple titration", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and\n      safety of flexible versus fixed dosing and simple versus stepwise titration with once daily\n      insulin degludec in inadequately treated subjects with type 2 diabetes."
        }, 
        "brief_title": "A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Current treatment with IGlar (insulin glargine) with or without OADs (oral\n             antidiabetic drug). All antidiabetic treatments should have been on-going for at\n             least 12 weeks prior to randomisation, and doses of OADs should have been stable in\n             this period of time. - Please note that a maximum of 3 OADs are allowed during this\n             trial: metformin, sulphonylurea (SU)/glinides, dipeptidyl peptidase 4 (DPP-IV)\n             inhibitors, alfa-glucosidaseinhibitors or pioglitazone.\n\n          -  Diagnosis of T2DM (type 2 diabetes mellitus) at the discretion of the investigator\n             for at least 26 weeks prior to visit 1 (Screening visit)\n\n          -  HbA1c 7.0-9.5% (both inclusive) by central laboratory analysis\n\n          -  Body mass index (BMI) equal to or below 35 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Any chronic disorder or severe disease which, in the opinion of the Investigator\n             might jeopardise subject's safety or compliance with the protocol\n\n          -  Stroke; decompensated heart failure New York Heart Association (NYHA) class III or\n             IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass\n             graft or angioplasty; all within the last 26 weeks prior to Visit 1 (Screening visit)\n\n          -  Impaired renal function, defined as serum-creatinine higher than or equal to 1.4\n             mg/dL for males and higher than or equal to 1.3 mg/dL for females\n\n          -  Current or past (within the last 5 years) malignant neoplasms (except basal cell and\n             squamous cell skin carcinoma)\n\n          -  Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria\n             in a period of 12 weeks prior to randomisation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "458", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01880736", 
            "org_study_id": "NN1250-4060", 
            "secondary_id": [
                "U1111-1137-0953", 
                "JapicCTI- 132164"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "IDeg Fixed dosing - Stepwise titration", 
                    "IDeg Fixed dosing - Simple titration"
                ], 
                "description": "Individual dose adjusted once weekly.  Administered subcutaneously (s.c., under the skin) once daily at the same time each day.  A maximum of 3 pre-trial OADs (oral anti-diabetic drugs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.", 
                "intervention_name": "insulin degludec", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "IDeg Flexible dosing - Stepwise titration", 
                    "IDeg Flexible dosing - Simple titration"
                ], 
                "description": "Individual dose adjusted once weekly. Administered subcutaneously (s.c., under the skin) once daily with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs (oral anti-diabetic drugs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.", 
                "intervention_name": "insulin degludec", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 22, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan", 
                    "zip": "103-0028"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in HbA1c ((%) glycosylated haemoglobin)", 
            "safety_issue": "No", 
            "time_frame": "Week 0, week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01880736"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in fasting plasma glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 26"
            }, 
            {
                "measure": "Responder for HbA1c (%) based on central laboratory assessment: HbA1c below 7.0% at end of trial", 
                "safety_issue": "No", 
                "time_frame": "After 26 weeks of treatment"
            }, 
            {
                "measure": "Incidence of treatment emergent adverse events (TEAEs)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-26"
            }, 
            {
                "measure": "Number of treatment emergent confirmed hypoglycaemic episodes (defined as severe hypoglycaemia and/or a measured plasma glucose (PG) less than 3.1 mmol/L (less than 56 mg/dL))", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-26"
            }, 
            {
                "measure": "Number of treatment emergent hypoglycaemic episodes according to the American Diabetes Association (ADA) definition", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-26"
            }, 
            {
                "measure": "Number of treatment emergent confirmed hypoglycaemic episodes in the maintenance period", 
                "safety_issue": "No", 
                "time_frame": "From 16 weeks to end of trial (week 27)"
            }, 
            {
                "measure": "Number of treatment emergent nocturnal (00:01-05:59 am) confirmed hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-26"
            }, 
            {
                "measure": "Number of treatment emergent nocturnal (00:01-05:59 am) confirmed hypoglycaemic episodes in the maintenance period", 
                "safety_issue": "No", 
                "time_frame": "From week 16 to end of trial (week 27)"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}